Sugi Predict

Sugi Predict / Compounds / SCHEMBL2490112

SCHEMBL2490112

SCHEMBL2490112

Cc1nc2c(F)cc(Br)cc2n1C(C)C

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PLK4 O00444 4/20 0.40
▸ CDK4 P11802 16/20 0.39
▸ CDK6 Q00534 11/20 0.39
▸ CDK2 P24941 4/20 0.39
▸ CDK1 P06493 12/20 0.38
▸ TBK1 Q9UHD2 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC10 Q969S8 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ CDK7 P50613 2/20 0.37
▸ CDK9 P50750 2/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCNE1 P24864 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30309559 1.00 PLK4 (0.40) PLK4CDK4CDK6CDK2CDK1
Hydrochloric Acid SCHEMBL31686442 0.98 PLK4 (0.39) PLK4CDK4CDK6CDK2CDK1
SCHEMBL21522868 0.83 NQO2 (0.38) PLK4CDK4CDK6CDK2
SCHEMBL30888966 0.83 NQO2 (0.38) PLK4CDK4CDK6CDK2
SCHEMBL20311307 0.83 PLK4 (0.41) PLK4CDK4CDK6CDK2CDK1
SCHEMBL30040639 0.83 ACACB (0.34) CDK4CDK6
SCHEMBL20987185 0.83 ACACB (0.34) CDK4CDK6
SCHEMBL21539413 0.82 CDK4 (0.40) CDK4CDK6CDK2CDK1CDK7
SCHEMBL20987169 0.81 CDK4 (0.36) CDK4CDK6CDK2
SCHEMBL30040756 0.81 CDK4 (0.36) CDK4CDK6CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119954659-A Preparation method of arbeli intermediate 昊宏(齐河)医药科技有限公司 2025-05-09 — — CN claimed
CN-119751416-A Preparation method of arbeli 重庆圣华曦药业股份有限公司 2025-04-04 — — CN claimed
CN-119462516-A Compound of formula I, preparation method and application thereof, and preparation method of Abeli intermediate compound A 广东莱佛士制药技术有限公司 2025-02-18 — — CN claimed
CN-112028834-B Synthesis method of Abelide intermediate 济南悟通生物科技有限公司 2022-03-29 — — CN claimed
CN-112028834-A Synthesis method of Abelide intermediate 济南悟通生物科技有限公司 2020-12-04 — — CN claimed
CN-111018789-A Synthetic method of 6-bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo [ D ] imidazole 睿辰康达生物医药(武汉)有限公司 2020-04-17 — — CN claimed
WO-2019102492-A1 CRYSTALLINE POLYMORPHS OF ABEMACICLIB MYLAN LABORATORIES LIMITED (IN) 2019-05-31 — — WO claimed
CN-119462516-B Compound of formula I, preparation method and application thereof, and preparation method of Abeli intermediate compound A 广东莱佛士制药技术有限公司 2025-10-14 — — CN disclosed
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 — — US disclosed
CN-120682157-A Synthesis method of arbeli intermediate 广东东阳光药业股份有限公司 2025-09-23 — — CN disclosed
US-12378232-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2025-08-05 — — US disclosed
EP-4592286-A1 MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR Artivila Biopharma (CN) 2025-07-30 — — EP disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 — — EP disclosed
WO-2015130540-A1 COMBINATION THERAPY FOR CANCER ELI LILLY AND COMPANY (US) 2015-09-03 — — WO disclosed
WO-2015101293-A1 KINASE INHIBITOR AND USE THEREOF 山东轩竹医药科技有限公司 2015-07-09 — — WO disclosed
EP-2379528-B1 PROTEIN KINASE INHIBITORS LILLY CO ELI (US) 2013-09-18 — — EP disclosed
EP-2379528-A1 PROTEIN KINASE INHIBITORS Eli Lilly and Company (US) 2011-10-26 — — EP disclosed
US-7855211-B2 such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases ELI LILLY AND COMPANY (US) 2010-12-21 — — US disclosed
WO-2010075074-A1 PROTEIN KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2010-07-01 — — WO disclosed
US-20100160340-A1 such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases ELI LILLY AND COMPANY 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160340-A1 such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases MKI67, PKD1, CCNI PLK4 129/4885CDK4 26/4885CDK6 86/4885
US-12378232-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK PLK4 119/4885CDK4 27/4885CDK6 29/4885
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PLK4 1693/4885CDK4 328/4885CDK6 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.